Endoglin (CD105) as a urinary and serum marker of prostate cancer

Kazutoshi Fujita, Charles M. Ewing, David Y S Chan, Leslie A. Mangold, Alan Wayne Partin, William B Isaacs, Christian Pavlovich

Research output: Contribution to journalArticle

Abstract

We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p = 0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73%, specificity 63%). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p = 0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67% and a specificity of 80%. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.

Original languageEnglish (US)
Pages (from-to)664-669
Number of pages6
JournalInternational Journal of Cancer
Volume124
Issue number3
DOIs
StatePublished - Feb 1 2009

Fingerprint

Prostatic Neoplasms
Biomarkers
Serum
Digital Rectal Examination
Urine
Prostatectomy
Biopsy
ROC Curve
Endoglin
Neoplasms
Prostate-Specific Antigen
Tumor Burden
Enzyme-Linked Immunosorbent Assay

Keywords

  • Biological markers
  • CD105
  • Clinical markers
  • Endoglin
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Endoglin (CD105) as a urinary and serum marker of prostate cancer. / Fujita, Kazutoshi; Ewing, Charles M.; Chan, David Y S; Mangold, Leslie A.; Partin, Alan Wayne; Isaacs, William B; Pavlovich, Christian.

In: International Journal of Cancer, Vol. 124, No. 3, 01.02.2009, p. 664-669.

Research output: Contribution to journalArticle

Fujita, Kazutoshi ; Ewing, Charles M. ; Chan, David Y S ; Mangold, Leslie A. ; Partin, Alan Wayne ; Isaacs, William B ; Pavlovich, Christian. / Endoglin (CD105) as a urinary and serum marker of prostate cancer. In: International Journal of Cancer. 2009 ; Vol. 124, No. 3. pp. 664-669.
@article{7a92ca167feb4e959feb3a5ac543b3b1,
title = "Endoglin (CD105) as a urinary and serum marker of prostate cancer",
abstract = "We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p = 0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73{\%}, specificity 63{\%}). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p = 0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67{\%} and a specificity of 80{\%}. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.",
keywords = "Biological markers, CD105, Clinical markers, Endoglin, Prostate cancer",
author = "Kazutoshi Fujita and Ewing, {Charles M.} and Chan, {David Y S} and Mangold, {Leslie A.} and Partin, {Alan Wayne} and Isaacs, {William B} and Christian Pavlovich",
year = "2009",
month = "2",
day = "1",
doi = "10.1002/ijc.24007",
language = "English (US)",
volume = "124",
pages = "664--669",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Endoglin (CD105) as a urinary and serum marker of prostate cancer

AU - Fujita, Kazutoshi

AU - Ewing, Charles M.

AU - Chan, David Y S

AU - Mangold, Leslie A.

AU - Partin, Alan Wayne

AU - Isaacs, William B

AU - Pavlovich, Christian

PY - 2009/2/1

Y1 - 2009/2/1

N2 - We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p = 0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73%, specificity 63%). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p = 0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67% and a specificity of 80%. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.

AB - We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p = 0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73%, specificity 63%). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p = 0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67% and a specificity of 80%. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.

KW - Biological markers

KW - CD105

KW - Clinical markers

KW - Endoglin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=58149290234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149290234&partnerID=8YFLogxK

U2 - 10.1002/ijc.24007

DO - 10.1002/ijc.24007

M3 - Article

VL - 124

SP - 664

EP - 669

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -